Biogen Reiterates Byooviz Will Not Be Meaningful In 2022
Launches Outside Of The US Scheduled For Early 2023
Biogen is looking for its ranibizumab biosimilar Byooviz to make a splash in 2023 as it continues to forecast falling biosimilars sales for 2022.
You may also be interested in...
Biogen expects impending biosimilar launches to stimulate new growth, while unfavorable market conditions have taken their toll on the company.
Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.
Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.